Alzamend Neuro, Inc. Common Stock (ALZN) is a publicly traded Healthcare sector company. As of May 21, 2026, ALZN trades at $1.18 with a market cap of $3.88M and a P/E ratio of -0.09. ALZN moved +23.76% today. Year to date, ALZN is -41.46%; over the trailing twelve months it is -65.91%. Its 52-week range spans $0.84 to $17.10. Analyst consensus is buy with an average price target of $25.00. Rallies surfaces ALZN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Alzamend’s AL001 Reduces Myo-Inositol in 17 of 18 Regions, Spares Glutamate: In a six-subject Phase II MRS study, two weeks of AL001 dosing showed reduction of myo-inositol in 17 of 18 brain regions versus eight regions with lithium carbonate. AL001 produced minimal glutamate changes in 10 regions versus widespread lithium disruption, suggesting a distinct neurochemical footprint and potential tolerability advantage.
| Metric | Value |
|---|---|
| Price | $1.18 |
| Market Cap | $3.88M |
| P/E Ratio | -0.09 |
| EPS | $-11.32 |
| Dividend Yield | 0.00% |
| 52-Week High | $17.10 |
| 52-Week Low | $0.84 |
| Volume | 221.07K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $4.50M |
| Gross Margin | 0.00% |
1 analysts cover ALZN: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $25.00.